کد مقاله کد نشریه سال انتشار مقاله انگلیسی نسخه تمام متن
2408560 1103180 2007 11 صفحه PDF دانلود رایگان
عنوان انگلیسی مقاله ISI
GSK's antigen-specific cancer immunotherapy programme: Pilot results leading to Phase III clinical development
موضوعات مرتبط
علوم زیستی و بیوفناوری ایمنی شناسی و میکروب شناسی ایمونولوژی
پیش نمایش صفحه اول مقاله
GSK's antigen-specific cancer immunotherapy programme: Pilot results leading to Phase III clinical development
چکیده انگلیسی

From the first evidence that the immune system could recognize tumors, different types of tumor antigens have been identified and deeply characterized. Several different approaches aimed at targeting these antigens have already been the subject of clinical studies. In this field, the GSK Biologicals’ approach relying on recombinant proteins combined with an immunological Adjuvant System in a specific clinical setting, has entertained hopes of developing a new class of well tolerated anti-cancer therapy. This methodology led to promising advances with MAGE-A3 immunotherapy in NSCLC and has the potential to be applied to all tumor types.

ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Vaccine - Volume 25, Supplement 2, 27 September 2007, Pages B61–B71
نویسندگان
, ,